Protocol Ledger

NCT07729462 · Phase III · RECRUITING

A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

Interventional Phase III clinical trial protocol NCT07729462 sponsored by Pfizer in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-26 Enrollment: 400 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07729462
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)400 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07729462
Protocol FieldVerified Registry Value
NCT IdentifierNCT07729462
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment400 participants (ESTIMATED)
Registered Start Date2026-08-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07729462
Hospital Research SiteLocationSite Profile
Hope Clinical ResearchCanoga Park, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI